Prior to the CDMO they developed a modified purification process which the previous tested batch had no issues with the specification. If the new modification has the same quality as the previous, I am expecting an announcement with met specification. With this announcement, the Patrys as a company will be renewed with confidence from old and new investors and the management will be acknowledged for their competency.
All in all this will change investors sentiment and will add better value as we are moving forward to the next stage of toxicology studies.
PAB Price at posting:
2.3¢ Sentiment: Hold Disclosure: Held
